TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03490578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive treadmill training
Description: Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
Study: NCT03564392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Based Behavioral Intervention
Description: This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
Study: NCT01226394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy plus HIPEC
Description: Laparotomy + HIPEC
Study: NCT02796638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Description: A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
Study: NCT01632657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sumatriptan
Description: Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection saline 0.5ml subcutaneously in recovery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single injection saline 0.5ml subcutaneously in recovery
Study: NCT00003088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV
Study: NCT01253798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group training
Description: Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group training
Description: Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
Study: NCT02732132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and Midazolam
Description: This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Fentanyl
Description: This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
Study: NCT02434705

Intervention type: OTHER
Intervention: Antigen (wheat base soy sauce) spray
Description: Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
Study: NCT01297595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
Study: NCT03637075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: intranasal administration of insulin (160 IU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo intranasal administration
Study: NCT01855399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coaching
Description: All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Coaching
Description: All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
Study: NCT03233295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 B.O.N. Injection
Description: cholecalciferol 200,000IU
Study: NCT03990805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline, 1 time injection
Study: NCT04033094

Intervention type: DRUG
Intervention: MorphaBond ER
Description: This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).

Intervention type: DRUG
Intervention: Comparator Drug
Description: This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
Study: NCT04397965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cascade Continuous Glucose Monitor
Description: Continuous Glucose Monitoring
Study: NCT02072525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo®
Description: One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
Study: NCT02679222

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: 20 g of coconut oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil + MCT
Description: 10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT
Description: 20 g of MCT (60 of C8+40 of C10)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil + tricaprylin
Description: 10 g coconut oil + 10 g tricaprylin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprylin
Description: 20 g tricaprylin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprin
Description: 20 g tricaprin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: No supplement taken on this visit
Study: NCT03238209

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise testing
Description: The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
Study: NCT02827084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Application of the Kinesio Taping with tension in the vatus mediallis muscle.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of the Kinesio Taping without tension in the vatus mediallis muscle.
Study: NCT03112343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm-based feedback messages
Description: ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Personal Health Record
Description: Subjects will save and send their health information to the server via the personal health record app

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Health Record
Description: Subjects will save and send their health information to the server via the personal health record app
Study: NCT02487576

Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate-rich (HC)
Description: 65% Carbohydrate; 20% Fat; 15% Protein

Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate-rich (HC)
Description: 65% Carbohydrate; 20% Fat; 15% Protein
Study: NCT02997748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
Study: NCT02565511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106 Immunotherapy
Description: Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CAD106
Description: Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520
Description: CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
Study: NCT02487576

Intervention type: OTHER
Group type: OTHER
Intervention: Fat-rich (HF)
Description: 35% Carbohydrate; 50% Fat; 15% Protein
Study: NCT02565511

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CNP520
Description: Placebo to CNP520 p.o. for the duration of the Treatment Epoch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alum
Description: Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum
Description: Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
Study: NCT01691235

Intervention type: DEVICE
Intervention: SIMpill device
Description: The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
Study: NCT01572805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin 3mg
Description: To receive sublingual 3 mg melatonin before spinal of anesthesia .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin 6mg
Description: To receive sublingual 6 mg melatonin before spinal of anesthesia .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: To receive sublingual placebo tablet before spinal of anesthesia .
Study: NCT03015220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
Study: NCT02084615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
Study: NCT01673256

Intervention type: DEVICE
Intervention: SJM Confirm ICM
Study: NCT03854565

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycocalyx measurement，respiratory mechanics measurement
Description: ELASA measure glycocalyx, measure plateau pressure, driving pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycocalyx measurement，respiratory mechanics measurement
Description: ELASA measure glycocalyx, measure plateau pressure, driving pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycocalyx measurement，respiratory mechanics measurement
Description: ELASA measure glycocalyx, measure plateau pressure, driving pressure
Study: NCT02280382

Intervention type: DEVICE
Group type: OTHER
Intervention: Femmeze®
Description: Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
Study: NCT01262040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Description: The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
Study: NCT01238757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Ventilation under Pressure Support
Description: Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive ventilation under NAVA
Description: 20 min session under non-invasive ventilation with NAVA
Study: NCT01778140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-specific computerized reminder
Description: The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-patient-specific computerized reminder
Description: The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
Study: NCT01434927

Intervention type: PROCEDURE
Intervention: Unsedated colonoscopy
Description: Patients were offered to undergo colonoscopy without routine premedication

Intervention type: PROCEDURE
Intervention: Unsedated colonoscopy
Description: Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
Study: NCT02636049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
Study: NCT02367196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT04907942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMA + Automated Text Message Intervention
Description: Intervention includes 3 weeks of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of automated text messages delivered twice a day, which content follows constructs from The Transactional Model of Stress and Coping.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA Alone
Description: Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate momentary affects.
Study: NCT04613076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me cuido y me siento mejor
Description: A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Treatment
Description: Enhanced Usual Treatment
Study: NCT00052494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride